 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Target Audience |
 |
Financial Support |
 |
Credit Information |
neuroscienceCME Chart Review
Premiere Date: Monday, April 19, 2010This activity offers CE credit for:
All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
Credit Expiration Date:
Tuesday, April 19, 2011
Faculty
Roger S. McIntyre, MD, FRCPC (Moderator)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Toronto, ON
Charles L. Bowden, MD
Clinical Professor of Psychiatry and Pharmacology
University of Texas Health Science Center
San Antonio, TX
Amit Anand, MD (Content/Peer Reviewer)
Professor of Psychiatry and Radiology
Indiana University
Bloomington, INStatement of Need
Optimal management of bipolar disorder begins with accurate diagnosis. The Depression and Bipolar Alliance reported that the misdiagnosis rate is 67% for bipolar patients with the most common misdiagnoses being unipolar depression (60%), anxiety disorder (26%), schizophrenia (18%), and borderline or antisocial personality disorder (17%).(1) When diagnosis is inaccurate or delayed, initial therapy is not properly derived or promptly delivered. In this series of neuroscienceCME Chart Reviews, the faculty will take participants through a series of patient cases focusing on assessment, treatment, and treatment adherence to improve the long-term management of patients with bipolar disorder. Faculty will engage participants in the discussion and development of best practice tips to apply in practice.
- Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-174.
Activity Goal
To implement strategies to improve assessment, treatment selection, and long-term outcomes in patients with bipolar mania.
Learning Objectives
At the end of this CE activity, participants should be able to:
- Build therapeutic alliances with patients with bipolar disorder in order to optimize adherence.
The following learning objectives pertain only to those requesting CNE credit:
- Identify factors that contribute to treatment nonadherence among patients with bipolar mania.
Target Audience
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in mental health.
Financial Support
Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge educational grants from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc., and from Pfizer Inc. in support of this CE activity.
Credit Information
CME Credit (Physicians):
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
It has been assigned approval code 82RPXJ-10. 0.5 contact hours will be awarded upon successful completion.CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs)
Universal Program Number:
376-999-10-009-L01-P (live presentation)
376-999-10-009-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
Disclosure Declaration
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
Dr. McIntyre has disclosed that he receives grants/research support from Eli Lilly and Company, Janssen-Ortho, Inc., and Shire Pharmaceuticals, as well as Private Industries or Non-Profit Funds: Stanley Medical Research Institute, National Alliance for Research on Schizophrenia and Depression (NARSAD). He serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, France Foundation, GlaxoSmithKline, Janssen-Ortho, Inc., H. Lundbeck A/S, Organon, Pfizer Inc., Schering-Plough Corporation, Shire Pharmaceuticals, and Solvay/Wyeth. He serves on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Eli Lilly and Company, Janssen-Ortho, Inc., H. Lundbeck A/S, Schering-Plough Corporation, and Wyeth Pharmaceuticals.
Dr. Bowden has disclosed that he serves as a consultant to Bristol-Myers Squibb Company, Sanofi-aventis, Schering-Plough Corporation, and Pfizer Inc. He receives grants from Abbott Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., National Institute of Mental Health, and Repligen Corporation.
Dr. Anand has disclosed that he has received honoraria from Pfizer Inc. as a consultant, and has received research grants from Eli Lilly and Company and AstraZeneca Pharmaceuticals LP as an independent investigator.Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Indiana University School of Medicine, CME Outfitters, LLC, the faculty, Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc., and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
CR-003-041910-99
